NCT01973725View on ClinicalTrials.gov

Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

September 30, 2018

Study Completion Date

December 31, 2018

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Icotinib Hydrochloride

Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Yuhong Li

OTHER

NCT01973725 - Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy | Biotech Hunter | Biotech Hunter